PEIJIA-B's revenue for the first half of the year was approximately 350-360 million yuan, a year-on-year increase of about 16.2%-19.5%
I'm PortAI, I can summarize articles.
PEIJIA-B announced that its revenue for the first half of 2025 is expected to be approximately RMB 350 million to RMB 360 million, representing a year-on-year growth of about 16.2% to 19.5%. The revenue growth is mainly attributed to the expansion of its market share in China's TAVR market, the launch of high-end product offerings, and strong performance of key neurointerventional products. During the reporting period, the total number of TAVR implants exceeded 2,050, a year-on-year increase of approximately 18.8%
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments